Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag alone or with rh-TPO for chemotherapy-induced thrombocytopenia in gynecologic malignancies
ChiCTR2200062611Phase 4Not yet recruiting
- Sponsor
- Xiangyang Central Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of hetrombopag and recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia (CIT) (3 arms), sponsored by Xiangyang Central Hospital. Primary endpoints: Percentage of patients whose platelet counts recovered to >= 100 x 10^9/L during the treatment period and Time required for platelet count to recover to >= 100 x 10^9/L during treatment. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
hetrombopagrecombinant human thrombopoietin
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2200062611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062611.